Trial Profile

A Phase I Clinical Study of PPL-103

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 29 Dec 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PPL 103 (Primary)
Indications Pain; Substance-related disorders
Focus Adverse reactions

Most Recent Events

21 Dec 2020 According to the Phoenix PharmaLabs media release, PPl-103 is expected to enter Phase I clinical trials in 2021.
12 Apr 2019 New trial record
08 Apr 2019 According to the Phoenix PharmaLabs media release, company anticipates to file Investigational Drug Application (IND) with the FDA within approximately 15 months.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com